+91-7680014141 sales@hbmdlifesciences.com Mon – Sat: 9AM – 6:30PM
HBMD Life Sciences Private Limited
News & Insights

Latest from the HBMD lab.

Catalog launches, partnerships & milestones.

Announcements, product catalog expansions, certifications, and company updates from HBMD Life Sciences.

Intermediates catalog launch Product Launch
January 2026

New: 89 API Intermediates & KSMs now available across 36 end-use APIs

Our expanded Intermediates catalog covers Acalabrutinib, Dabigatran, Solifenacin, Luliconazole, Voriconazole and more — produced under ICH Q7 GMP guidance with full analytical characterisation.

See Intermediates
NDSRI synthesis capability Capability
November 2025

HBMD launches dedicated Nitrosamine & NDSRI synthesis capability

In response to tightening global regulatory guidance on nitrosamines and nitrosamine-drug substance-related impurities (NDSRIs), HBMD has opened a dedicated high-security synthesis unit for trace-level nitrosamine standards.

Learn More
Agro chemicals catalog New Vertical
September 2025

Agrochemical reference standards catalog goes live

HBMD's new agrochemical vertical launches with Pyriproxyfen, Cymoxanil, Clodinafop Propargyl, and Bispyribac-sodium — supporting method development, residue analysis and regulatory compliance for crop-protection R&D labs.

See Catalog
ISO certification achievement Certification
July 2025

HBMD laboratory completes ISO 9001:2015 quality certification audit

The successful certification audit validates our quality management system end-to-end — from raw material intake to Certificate of Analysis issuance — aligning our workflows with international best practice.

About Our QMS
Lab expansion Milestone
April 2025

HBMD marks 10 years of R&D excellence in India

From a two-bench lab in 2014 to a team of 30+ scientists serving 50+ global pharma clients — a decade of focused chemistry, and the foundation for our next chapter of growth.

Our Story
Partnership announcement Partnership
February 2025

Multi-year CRO partnership signed with a top European generic pharma

HBMD has been selected as a preferred impurity synthesis and analytical development partner — a three-year engagement covering 40+ APIs across cardiovascular, CNS and oncology therapeutic areas.

CRO Services
Conference presentation Conference
December 2024

HBMD presents impurity profiling case studies at CPhI India 2024

Dr. H. M. Bharath, Managing Director, delivered a technical session on the synthesis and characterisation of genotoxic impurities and NDSRIs at CPhI India, Hyderabad — drawing participation from 100+ pharma R&D professionals.

Get in Touch

Don't miss an update.

Subscribe to our quarterly newsletter — catalog expansions, regulatory insights, and chemistry how-tos. No spam, unsubscribe anytime.